1. Home
  2. RDI vs ALLR Comparison

RDI vs ALLR Comparison

Compare RDI & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RDI

Reading International Inc

HOLD

Current Price

$1.11

Market Cap

23.6M

ML Signal

HOLD

Logo Allarity Therapeutics Inc.

ALLR

Allarity Therapeutics Inc.

HOLD

Current Price

$1.26

Market Cap

19.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDI
ALLR
Founded
1937
2004
Country
United States
United States
Employees
2025
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.6M
19.3M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RDI
ALLR
Price
$1.11
$1.26
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.50
AVG Volume (30 Days)
22.2K
184.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$13.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.94
$0.61
52 Week High
$1.65
$2.35

Technical Indicators

Market Signals
Indicator
RDI
ALLR
Relative Strength Index (RSI) 51.96 61.36
Support Level $1.07 $0.99
Resistance Level $1.16 $1.31
Average True Range (ATR) 0.06 0.11
MACD 0.01 0.04
Stochastic Oscillator 74.36 67.96

Price Performance

Historical Comparison
RDI
ALLR

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About ALLR Allarity Therapeutics Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.

Share on Social Networks: